TP53 and colorectal carcinoma: We recently reported this phenomenon in Drosophila CRC models, both preclinically and in complex fly avatars as a part of a clinical trial: compared to oncogenic RAS alone, additionally targeting tumour suppressors APC and P53 (“RAP”) consistently led to emergent drug resistance [3, 4].